Feasibility of home-based ELISA capillary blood self-testing for anti-SARS-CoV-2 antibodies.
Antibodies
COVID-19
Covid-19, Coronavirus disease of 2019
ELISA, Enzyme-linked immunosorbent assays
IgG, Immunoglobulin G
OR, Odd-ratio
RT-PCR, Real-time reverse transcription–polymerase chain reaction
SARS-CoV-2
SARS-CoV-2, Severe acute respiratory syndrome coronavirus 2
Serological testing
Journal
Practical laboratory medicine
ISSN: 2352-5517
Titre abrégé: Pract Lab Med
Pays: Netherlands
ID NLM: 101690848
Informations de publication
Date de publication:
Aug 2022
Aug 2022
Historique:
received:
10
01
2022
revised:
17
06
2022
accepted:
08
07
2022
entrez:
18
7
2022
pubmed:
19
7
2022
medline:
19
7
2022
Statut:
ppublish
Résumé
Serological assays for the presence of anti-SARS-CoV-2 antibodies are crucially needed for research and monitoring of the SARS-CoV-2 pandemic. Antibodies are reliability detected in capillary blood, a minimally invasive and cost-effective alternative to venous blood testing. However, there is a limited knowledge on feasibility of capillary blood self-sampling. This study compared the feasibility of capillary blood self-testing in people aged less than 65 Data were collected in a prospective study in Switzerland (n = 106). Capillary blood was collected using the Hem-Col® (no additive) device. Feasibility was assessed using 1) collecting the recommended amount of capillary blood and 2) achieving all steps of capillary blood collection. A sample of 5 ml of venous blood was also collected. For the primary objective, 86.2%/62.1% of patients aged less than 65 collected the recommended amount of capillary blood/achieved all steps Capillary blood self-testing appeared as a feasible and reliable alternative to venous blood testing. Such alternative would improve access to serological testing and spare health care resources. However, the difference between age groups should be considered when using self-sampling devices. Help should be developed for older people, such as phone counseling or encouraging asking younger family members for help.
Identifiants
pubmed: 35846110
doi: 10.1016/j.plabm.2022.e00290
pii: S2352-5517(22)00029-4
pmc: PMC9273287
doi:
Types de publication
Journal Article
Langues
eng
Pagination
e00290Informations de copyright
© 2022 The Authors.
Déclaration de conflit d'intérêts
None.
Références
Microbiol Spectr. 2021 Oct 31;9(2):e0017821
pubmed: 34549995
J Clin Virol. 2021 Aug;141:104855
pubmed: 34144453
Sci Rep. 2020 Nov 19;10(1):20188
pubmed: 33214612
J Public Health Res. 2020 Dec 22;9(4):1986
pubmed: 33409245
Int J Infect Dis. 2021 Apr;105:374-376
pubmed: 33684560
Rev Med Suisse. 2020 Sep 16;16(706):1695-1698
pubmed: 32936552
PLoS One. 2017 Oct 20;12(10):e0186722
pubmed: 29053737
Sci Rep. 2021 May 4;11(1):9475
pubmed: 33947894
Clin Infect Dis. 2021 May 4;72(9):e384-e393
pubmed: 32785665
BMJ Open. 2021 Jun 18;11(6):e044242
pubmed: 34145007
Front Med (Lausanne). 2021 Jul 20;8:685124
pubmed: 34355004
Lancet Child Adolesc Health. 2021 Apr;5(4):256-264
pubmed: 33571450
Sci Rep. 2021 Apr 8;11(1):7754
pubmed: 33833246
PLoS One. 2020 Oct 15;15(10):e0240779
pubmed: 33057446
Prev Med. 2021 Sep;150:106696
pubmed: 34174252
Proc Natl Acad Sci U S A. 2021 May 4;118(18):
pubmed: 33945500
Sci Rep. 2021 May 10;11(1):9819
pubmed: 33972607